Jim Murray: Volte-face by the European Medicines Agency?

The European Medicines Agency (EMA) has recently published to a targeted audience final consultation draft papers on its new “proactive” transparency policy on clinical trial results. As reported, information published under the draft policy would be on a screen-read only basis, would not include commercially confidential information (CCI) as defined by the EMA, would be subject […]

Read More…

Richard Smith: The polypill reaches the plateau of productivity

“I’m outraged,” said Robert Beaglehole, former director at WHO responsible for non communicable disease, at the end of the second polypill summit in Melbourne recently. He’s outraged because the world is failing to respond adequately to the “global public health crisis” of non communicable disease (NCD) that is destroying lives in low and middle income […]

Read More…